|

Trifluridine-tipiracil Clinical Trials

12 actively recruiting trials across 7 locations

-1 trial since July 2026

Also known as: (choose one combination) : oxalipatin or irinotecan, Bevacizumab, FTD-TPI, FTD/TPI, FTP/TPI +4 more

Pipeline

Phase 1: 2Phase 2: 6Phase 3: 2Phase 1/2: 2

Top Sponsors

  • Sun Yat-sen University2
  • The Methodist Hospital Research Institute1
  • Qilu Hospital of Shandong University1
  • Parabilis Medicines, Inc.1
  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1

Indications

Other5 trials

Phoenix, Arizona1 trial

Scottsdale, Arizona1 trial

New Haven, Connecticut1 trial

North Haven, Connecticut1 trial

East Brunswick, New Jersey1 trial

Cleveland, Ohio1 trial

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2

Houston, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.